BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that members of the senior management team will present a company overview at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016, at 11:20 a.m. Eastern Time and at the Barclays Capital Global Healthcare Conference on Wednesday, March 16, 2016, at 4:20 p.m. Eastern Time.
The live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. The replays of the webcasts will be available for 14 days following each webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for peanut allergy and other life-threatening food allergies. The company’s characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to obtain clinically meaningful desensitization to food allergens. Aimmune Therapeutics initiated the Phase 3 PALISADE trial of its lead product, AR101, a complex mixture of natural peanut proteins and pharmaceutical-grade ingredients for the treatment of peanut allergy, one of the most common food allergies, in early 2016. AR101 has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age. For more information, please see www.aimmune.com.